Significance of Serum Amyloid A on the Prognosis in Patients With Renal Cell Carcinoma

Cancer. 2001 Oct 15;92(8):2072-5. doi: 10.1002/1097-0142(20011015)92:8<2072::aid-cncr1547>3.0.co;2-p.

Abstract

Background: Evidence of systemic inflammation, i.e., elevation of serum C-reactive protein, interleukin-6, and/or the erythrocyte sedimentation rate, is correlated to poorer prognosis of patients with renal cell carcinoma (RCC). Serum amyloid A (SAA) has been recognized mainly as acute-phase reactant.

Methods: Serum SAA from 72 patients with RCC were examined. Thirty-eight of 72 patients with RCC had elevated SAA compared with 17 healthy donors.

Results: The disease specific survival rate was significantly lower in the elevated SAA group, and SAA level was shown to be an independent prognostic factor by univariate and multivariate analysis.

Conclusions: Evaluation of serum SM level in RCC patients may be a useful prognostic indicator.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Biomarkers / blood
  • C-Reactive Protein / metabolism
  • Carcinoma, Renal Cell / blood*
  • Humans
  • Kidney Neoplasms / blood*
  • Middle Aged
  • Prognosis
  • Proportional Hazards Models
  • Serum Amyloid A Protein / metabolism*
  • Survival Analysis

Substances

  • Biomarkers
  • Serum Amyloid A Protein
  • C-Reactive Protein